Tags

Type your tag names separated by a space and hit enter

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Biomed Pharmacother. 2011 Jul; 65(4):303-6.BP

Abstract

BACKGROUND

In patients with chronic hepatitis C, rapid HCV-RNA clearance under treatment might allow shorter treatment duration without modifying the sustained virological response (SVR) rate. This study evaluated the impact of rapid virological response (RVR) in HCV genotype 1b infection management.

METHODS

In an open-label trial, 180 patients received standard doses of peginterferon alfa-2a plus ribavirin. Those with undetectable serum HCV-RNA at week 6 (RVR) received 24-week short-course treatment; patients with undetectable HCV-RNA at week 12 (early responders [ER]) received 48-week "standard of care" treatment; patients with positive HCV-RNA at week 12 (non-responders [NR]) stopped the treatment. Study end-point was to determine SVR rate at week 24.

RESULTS

The following responses were observed: 24% RVR, 44% ER, 32% NR. Among RVR subjects, HCV-RNA baseline levels and age were significantly lower (P=0.038 and 0.035 respectively) than in non-RVR patients. At follow-up, 91% of RVR and 33% of ER patients achieved SVR. Among those with RVR, patients experiencing post-therapy relapse were older than those who achieved a SVR (P=0.028).

CONCLUSIONS

Chronic HCV-1b patients, achieving RVR with a 24-week treatment regimen, attained excellent SVR rates. In a cost-effective therapeutic approach, all HCV-1b patients eligible for therapy may have a short duration therapy on the basis of RVR.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, Molinette Hospital, 88 Corso Bramante, 10100 Turin, Italy. renato.bonardi@hotmail.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

21723079

Citation

Bonardi, Renato, et al. "Short Duration Treatment in Genotype 1 Chronic Hepatitis C Patients With Rapid Virologic Response to Pegylated Interferon Plus Ribavirin." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 65, no. 4, 2011, pp. 303-6.
Bonardi R, Tabone M, Manca A, et al. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomed Pharmacother. 2011;65(4):303-6.
Bonardi, R., Tabone, M., Manca, A., Pellicano, R., Ciancio, A., & Rizzetto, M. (2011). Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 65(4), 303-6. https://doi.org/10.1016/j.biopha.2011.03.004
Bonardi R, et al. Short Duration Treatment in Genotype 1 Chronic Hepatitis C Patients With Rapid Virologic Response to Pegylated Interferon Plus Ribavirin. Biomed Pharmacother. 2011;65(4):303-6. PubMed PMID: 21723079.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. AU - Bonardi,Renato, AU - Tabone,Marco, AU - Manca,Aldo, AU - Pellicano,Rinaldo, AU - Ciancio,Alessia, AU - Rizzetto,Mario, Y1 - 2011/05/30/ PY - 2011/01/07/received PY - 2011/03/01/accepted PY - 2011/7/5/entrez PY - 2011/7/5/pubmed PY - 2011/12/13/medline SP - 303 EP - 6 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 65 IS - 4 N2 - BACKGROUND: In patients with chronic hepatitis C, rapid HCV-RNA clearance under treatment might allow shorter treatment duration without modifying the sustained virological response (SVR) rate. This study evaluated the impact of rapid virological response (RVR) in HCV genotype 1b infection management. METHODS: In an open-label trial, 180 patients received standard doses of peginterferon alfa-2a plus ribavirin. Those with undetectable serum HCV-RNA at week 6 (RVR) received 24-week short-course treatment; patients with undetectable HCV-RNA at week 12 (early responders [ER]) received 48-week "standard of care" treatment; patients with positive HCV-RNA at week 12 (non-responders [NR]) stopped the treatment. Study end-point was to determine SVR rate at week 24. RESULTS: The following responses were observed: 24% RVR, 44% ER, 32% NR. Among RVR subjects, HCV-RNA baseline levels and age were significantly lower (P=0.038 and 0.035 respectively) than in non-RVR patients. At follow-up, 91% of RVR and 33% of ER patients achieved SVR. Among those with RVR, patients experiencing post-therapy relapse were older than those who achieved a SVR (P=0.028). CONCLUSIONS: Chronic HCV-1b patients, achieving RVR with a 24-week treatment regimen, attained excellent SVR rates. In a cost-effective therapeutic approach, all HCV-1b patients eligible for therapy may have a short duration therapy on the basis of RVR. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/21723079/Short_duration_treatment_in_genotype_1_chronic_hepatitis_C_patients_with_rapid_virologic_response_to_pegylated_interferon_plus_ribavirin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(11)00036-9 DB - PRIME DP - Unbound Medicine ER -